Johns Hopkins Bloomberg School of Health is leading the way
<[link removed]>
John,
Since the outset of the global pandemic, teams at the Johns Hopkins Bloomberg
School of Public Health have been moving quickly to develop and test a
treatment for COVID-19. Their work has focused on convalescent plasma therapy,
which uses a transfusion of blood plasma from COVID-19 survivors to provide
antibodies that can treat or prevent infection in others.
The treatment has shown promise -- and its development has moved at an
unprecedented pace. "On March 1st, 2020, no convalescent plasma was being used
in the United States," says Dr. Arturo Casadevall, the lead researcher on the
project at the Johns Hopkins Bloomberg School of Public Health. "By the end of
the month, people were being treated."
In late March, Bloomberg Philanthropies provided $3 million to fund broader
research and testing along with the State of Maryland. And today, the program
is taking another step forward: The Johns Hopkins Bloomberg School of Public
Health will soon lead two nationwide clinical trials to further assess the
potential of the therapy.
To learn more about convalescent plasma therapy and how it might be used to
fight COVID-19, watch this video from the Johns Hopkins Bloomberg School of
Public Health:
<[link removed]>
WATCH NOW
<[link removed]>
In the video, Dr. Casadevall explains how convalescent blood plasma can be
used to treat or prevent COVID-19 -- and gives a look inside the work taking
place to help provide treatment and immunity with convalescent plasma.
As the research moves into national trials, take a moment to learn about the
potential of convalescent blood plasma to help address the COVID-19 pandemic:
[link removed]
<[link removed]>
We're grateful to all of the doctors and researchers at the Johns Hopkins
Bloomberg School of Public Health for all they're doing to help us stay healthy
-- and stay hopeful.
Thanks,
Bloomberg Philanthropies
<[link removed]>
<[link removed]>
<[link removed]>
Click here to unsubscribe
<[link removed]>
.
Bloomberg Philanthropies
All content © 2020. All rights reserved.